Pain management最新文献

{"title":"Effect of Citrus Aurantium L. on pain and blood pressure in patients undergoing hand reconstructive surgery.","authors":"Farideh Askari, Farzaneh Ghaffari, Nasrin Alaee, Mohsen Naseri, Akram Tayanloo-Beik","doi":"10.1080/17581869.2025.2515814","DOIUrl":"10.1080/17581869.2025.2515814","url":null,"abstract":"<p><strong>Background and purpose: </strong>Postoperative pain and blood pressure are common patient complaints. This study examined the effects of Citrus Aurantium (CA) on pain and blood pressure in patients undergoing hand reconstructive surgery.</p><p><strong>Methods: </strong>A double-blind, randomized clinical trial was conducted with 76 patients. The control group received a placebo, while the intervention group received CA essential oil. Blood pressure and pain levels were recorded before the intervention, and at 30 minutes and one-hour post-surgery. Data collection used blood pressure sheets, numerical visual pain scales, and demographic questionnaires.</p><p><strong>Result: </strong>The intervention group showed significantly greater pain reduction than the control group (<i>p</i> = 0.001), with CA increasing the likelihood of pain reduction by 1.73 times (Exp(B) = 1.73). Systolic and diastolic blood pressure significantly decreased post-intervention (<i>p</i> = 0.001, <i>p</i> = 0.005), but differences were not significant after 30 minutes and one hour after (<i>p</i> > 0.05). CA increased the likelihood of systolic blood pressure reduction by 16.87 times (Exp(B) = 16.78), with no effect on diastolic pressure.</p><p><strong>Conclusion: </strong>CA facilitates pain and blood pressure reduction in aromatherapy, suggesting its use as a simple, inexpensive, and noninvasive method for postoperative pain management.</p>","PeriodicalId":20000,"journal":{"name":"Pain management","volume":" ","pages":"491-500"},"PeriodicalIF":1.5,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12320857/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144576101","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ankylosing spondylitis management: a narrative review of radiofrequency ablation and naproxen.","authors":"Akash Patel, Dev Patel, John DesRochers, Abdullah Noory, Brandon Goodwin, Don D Shamilov, David F Lo, Richard Jermyn","doi":"10.1080/17581869.2025.2518046","DOIUrl":"10.1080/17581869.2025.2518046","url":null,"abstract":"<p><p>Axial spondyloarthritis (axSpA) is a chronic inflammatory disease primarily affecting the spine and sacroiliac joints, causing pain, stiffness, and reduced mobility. Its pathophysiology remains unclear, complicating treatment development. Management aims to alleviate symptoms and control inflammation, but targeted strategies are lacking. This study compared the efficacy of radiofrequency ablation (RFA) and naproxen in axSpA treatment. A PubMed search was conducted on 14 March 2023 and 27 May 2025. RFA is a minimally invasive procedure that targets nerve endings to block pain signals, while naproxen is a non-steroidal anti-inflammatory drug (NSAID) that reduces inflammation. We conducted a narrative review of axSpA patients treated with either RFA or naproxen, assessing pain relief, functional improvement, and quality of life. Results showed that RFA was significantly more effective than naproxen in managing chronic pain. Patients receiving RFA reported greater pain reduction and better functional outcomes compared to those on naproxen. RFA provided prolonged relief, while naproxen's effectiveness diminished over time, limiting its long-term benefit. These findings suggest that RFA should be considered a preferred treatment for axSpA patients seeking long-term pain relief and improved quality of life. This study supports RFA's role in managing inflammatory spinal conditions and informs optimal axSpA treatment strategies.</p>","PeriodicalId":20000,"journal":{"name":"Pain management","volume":" ","pages":"519-526"},"PeriodicalIF":1.5,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12320818/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144275642","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of temporo-parietal fascia trigger point release in the management of tension-type headache: a single-blinded RCT.","authors":"Sandhya Shrivastav, Sneha Mittal, Sunita Sharma, Amit Kumar","doi":"10.1080/17581869.2025.2527616","DOIUrl":"10.1080/17581869.2025.2527616","url":null,"abstract":"<p><strong>Background: </strong>The study aimed to investigate the effects of Temporoparietal Fascia trigger point release in subjects with Tension Type Headache (TTH) and on decreasing pain intensity and head and neck disability.</p><p><strong>Methods: </strong>40 subjects were randomly assigned to either Group 1 (intervention group) or Group 2 (control group) and received treatment for 10 days. Outcome measures, including the Visual Analog Scale (VAS) for pain intensity, Neck Disability Index (NDI) for neck disability, Headache Disability Inventory (HDI) for headache disability, and Pressure Pain Threshold (PPT) were used. Assessments were conducted in both groups before and after the 10-day intervention period.</p><p><strong>Result: </strong>Both groups exhibited statistically significant improvements in pain intensity, neck and headache disability, and pressure pain threshold after 10 days of intervention (<i>p</i> = 0.001). However, the intervention group showed greater clinical improvement compared to the control group. Between-group analysis revealed significant differences favoring the intervention group in VAS (<i>t</i> = 10.63), NDI (<i>t</i> = 7.81), HDI (<i>t</i> = 8.00), and PPT (<i>t</i> = 2.60), indicating that trigger point release in the temporo-parietal fascia was more effective in reducing symptoms and enhancing pain threshold.</p><p><strong>Conclusion: </strong>The study concluded that Myofascial trigger points (MTrPs) release is notably effective in pain reduction, as evidenced by greater clinical improvement in the intervention group compared to the control group. Both groups experienced similar benefits in reducing head and neck-related disabilities and increasing pain pressure thresholds.</p><p><strong>Clinical trial registration: </strong>www.ctri.nic.in, identifier: CTRI/2023/06/054085.</p>","PeriodicalId":20000,"journal":{"name":"Pain management","volume":" ","pages":"509-517"},"PeriodicalIF":1.5,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12320840/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144619690","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role of liposomal bupivacaine in pain management after the NOPAIN act.","authors":"Yash Shah, Anthony Barisano, Eric Ly, Vendhan Ramanujam","doi":"10.1080/17581869.2025.2525740","DOIUrl":"10.1080/17581869.2025.2525740","url":null,"abstract":"","PeriodicalId":20000,"journal":{"name":"Pain management","volume":" ","pages":"449-451"},"PeriodicalIF":1.5,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12320842/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144507522","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preoperative cryoneurolysis for peri- and postoperative pain in total knee arthroplasty: a systematic review and pooled analysis.","authors":"Brandon Goodwin, Hanna Brancaccio, Mitchell Kaplan, Valerie Rome, Sameer Shah, Sweta Mukhopadhyay, Seungkyu Park, Gilbert Siu","doi":"10.1080/17581869.2025.2522063","DOIUrl":"10.1080/17581869.2025.2522063","url":null,"abstract":"<p><strong>Background: </strong>Cryoneurolysis is seeing increased implementation in total knee arthroplasty (TKA), providing postoperative analgesia through preoperative cryoneurolysis of peripheral nerves. Thus, we are conducting this systematic review and meta-analysis to determine cryoneurolysis' efficacy in providing analgesia and improvements in recovery times for patients undergoing TKA.</p><p><strong>Methods: </strong>We conducted a comprehensive search using five databases including PubMed, Cochrane Library, Web of Science, Embase, and Scopus. The screened articles were assessed for inclusion of primary outcomes: pain scores before nerve cryoablation, peri- and post-operative pain scores in TKA, length of pain relief, patient demographics, and type of pain score employed. The Higgins I² test served to discern the degree of heterogeneity between included studies. Cohen's d was utilized to interpret the pooled effect size of the studies.</p><p><strong>Results: </strong>Our search yielded six articles that met our inclusion criteria. The overall effect size illustrated a d = 1.468 (95% CI: 1.084-1.851; <i>p</i> < 0.001) for the Visual Analog Score (VAS), Numerical Rating Score (NRS), and Patient-Reported Outcomes Measurement Information System (PROMIS) pain subscore. Each individual study possessed a large effect size.</p><p><strong>Conclusion: </strong>Our comprehensive review and meta-analysis indicated that cryoneurolysis provides effective pain management, providing TKA patients with significant pain reduction for 6-12 weeks post-surgery. Furthermore, improvements were observed in patient-centered outcomes: mobility, return to routine activities, and overall satisfaction. Future studies should be conducted to determine the long-term efficacy of cryoneurolysis and the appropriate timing and duration of cryoneurolysis to maximize its analgesic abilities.</p><p><strong>Protocolregistration: </strong>www.crd.york.ac.uk/prospero identifier is CRD42024542005.</p>","PeriodicalId":20000,"journal":{"name":"Pain management","volume":" ","pages":"527-534"},"PeriodicalIF":1.5,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12320839/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144560771","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Eptinezumab for migraine prevention after other treatments fail: a plain language summary of publications.","authors":"Messoud Ashina, Elena Ruiz de la Torre, Line Pickering Boserup, Anders Ettrup, Amaal J Starling","doi":"10.1080/17581869.2025.2514425","DOIUrl":"10.1080/17581869.2025.2514425","url":null,"abstract":"","PeriodicalId":20000,"journal":{"name":"Pain management","volume":" ","pages":"453-466"},"PeriodicalIF":1.5,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12320844/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144584542","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"STIMFIX™ anchoring in percutaneous spinal cord stimulation trials: interim analysis of a multicenter study.","authors":"Maja Green, Lakshmi Narra, Saurabh Dang, Jack Diep, Dipan Patel, Philip Lim, Joseph Atallah, Krishnan Chakravarthy","doi":"10.1080/17581869.2025.2527576","DOIUrl":"10.1080/17581869.2025.2527576","url":null,"abstract":"<p><strong>Aims: </strong>Lead migration during percutaneous spinal cord stimulation (SCS) trials can undermine therapeutic efficacy. This study evaluates the effectiveness of the novel, noninvasive STIMFIX anchoring system in reducing lead migration compared to conventional anchoring techniques.</p><p><strong>Patients & methods: </strong>This interim analysis included two prospectively collected cohorts. Group 1 (<i>n</i> = 28) was a randomized, single-center trial comparing three anchoring methods: sutures (<i>n</i> = 9), adhesive tape (<i>n</i> = 10), and manufacturer-provided anchors (<i>n</i> = 9). Group 2 (<i>n</i> = 20) was a multicenter, open-label, non-randomized study using STIMFIX anchors. Lead migration was measured via standardized fluoroscopic imaging on Days 1 and 7.</p><p><strong>Results: </strong>Mean lead migration in Group 1 was 33.5 mm (manufacturer anchor), 29.4 mm (tape), and 21.1 mm (sutures), with no significant differences between groups (<i>p</i> = 0.404). Group 2 demonstrated an average lead migration of 19.5 mm with STIMFIX. No major adverse events were reported; one case of minor skin irritation resolved without intervention.</p><p><strong>Conclusions: </strong>STIMFIX demonstrated reduced lead migration compared to conventional methods, with favorable safety and ease of application. These findings support its use as a promising advancement in SCS trial anchoring.</p><p><strong>Clinical trial registration: </strong>www.clinicaltrials.gov identifier is NCT05651646.</p>","PeriodicalId":20000,"journal":{"name":"Pain management","volume":" ","pages":"477-489"},"PeriodicalIF":1.5,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12320872/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144584544","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of diamagnetic therapy to manage a patient with degenerative cervical myelopathy and drug's intolerance.","authors":"Vincenzo Rania, Gianmarco Marcianò, Cristina Vocca, Caterina Palleria, Lucia Muraca, Pietro Romeo, Felipe Torres, Luca Gallelli","doi":"10.1080/17581869.2025.2523729","DOIUrl":"10.1080/17581869.2025.2523729","url":null,"abstract":"<p><p>Degenerative cervical myelopathy (DCM) is a common condition with a prevalence of 24.2% in the healthy population, and 35.3% in patients older than 60 years. The management of this clinical condition is difficult and implies chronic management of patients. The risk of drug abuse is very high and may lead to important long-term consequences. Finding a therapeutic option capable to reduce the number of prescribed drugs and with few side effects is very important in DCM. We report a 44-year-old Caucasian woman who was diagnosed with DCM. Her medical history revealed that despite using multiple medications, she did not show any signs of improvement. She declined the surgical treatment as well. Following clinical assessment, a diamagnetic pump treatment with pulsed electromagnetic fields for 3 months (once-twice weekly for 30 min, magnetic flux density 86 mt at the site of treatment) resulted in a clinical improvement. The benefits of diamagnetic therapy were three-faced including pain improvement, functional status, and imaging (magnetic resonance imaging (MRI) showing bone marrow edema reduction and myelopathy improvement). This is the first case report in our knowledge to prove the effectiveness of diamagnetic therapy in DCM, alongside imaging and functional improvement.</p>","PeriodicalId":20000,"journal":{"name":"Pain management","volume":" ","pages":"373-378"},"PeriodicalIF":1.4,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12218747/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144369136","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Repurposed versus disease-specific medicinals for the prophylaxis of migraine: an updated systematic review.","authors":"Savvas-Ilias Christofilos, Theodoros Mavridis, Viktor Gkotzamanis, Sofia Vasilopoulou, Christina I Deligianni, Dimos-Dimitrios Mitsikostas","doi":"10.1080/17581869.2025.2509474","DOIUrl":"10.1080/17581869.2025.2509474","url":null,"abstract":"<p><strong>Background: </strong>Gepants, selective antagonists of the calcitonin gene-related peptide (CGRP) receptor, and monoclonal antibodies targeting CGRP or its receptor (anti-CGRP mAbs) are promising migraine treatments, demonstrating superior tolerability than traditional preventives. While their efficacy over placebo is established, their comparative benefit-risk profiles remain to be fully elucidated.</p><p><strong>Objective: </strong>To indirectly compare the benefit-risk ratios of gepants with anti-CGRP mAbs and repurposed preventives.</p><p><strong>Methods: </strong>A comprehensive search of PubMed/MEDLINE and ClinicalTrials.gov was conducted to identify phase-3, placebo-controlled trials of gepants (atogepant, rimegepant), anti-CGRP mAbs (eptinezumab, erenumab, fremanezumab, galcanezumab), and traditional treatments (propranolol, topiramate, onabotulinumtoxinA). The number needed to treat (NNT) for achieving ≥50% reduction in migraine days and the number needed to harm (NNH) for adverse effects were calculated to determine the likelihood to help versus harm (LHH) values.</p><p><strong>Results: </strong>Twenty-seven studies were included: 15 of mAbs, 4 of gepants, 2 of onabotulinumtoxin A, and 6 of standard treatments. Atogepant and fremanezumab exhibited the highest LHH in episodic migraine, and galcanezumab and eptinezumab performed favorably in chronic migraine concerning treatment discontinuation and treatment-related adverse effects.</p><p><strong>Conclusions: </strong>Anti-CGRP/R medications present a more favorable benefit/risk ratio than traditional treatments. These findings, combined with individual patient histories and preferences, can inform clinical decision-making.</p>","PeriodicalId":20000,"journal":{"name":"Pain management","volume":" ","pages":"425-439"},"PeriodicalIF":1.5,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12218587/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144187608","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of intra-articular opioid injections for managing temporomandibular joint nociception: a systematic review.","authors":"Madhuli Bhide, P Emile Rossouw, Fawad Javed","doi":"10.1080/17581869.2025.2517523","DOIUrl":"10.1080/17581869.2025.2517523","url":null,"abstract":"<p><strong>Aim: </strong>This systematic review evaluated randomized controlled trials (RCTs) investigating the effectiveness of intra-articular opioid injections for managing temporomandibular joint (TMJ) pain.</p><p><strong>Methods: </strong>A comprehensive search of indexed databases and Google Scholar was conducted following PRISMA guidelines. Included studies assessed self-reported TMJ pain and maximum mouth opening (MMO) as primary and secondary outcomes, respectively. Risk of bias (RoB) was evaluated using the Cochrane tool, and evidence certainty was rated using the GRADE framework.</p><p><strong>Results: </strong>Ten RCTs met the inclusion criteria, with follow-up periods ranging from 30 minutes to 6 months. Six trials demonstrated significant pain reduction after opioid injections, while one reported no difference following morphine use. Another study found mepivacaine more effective than morphine or saline. Regarding MMO, one trial showed no effect of morphine, whereas two trials found that 1 mg morphine or 1 ml buprenorphine led to greater improvements than 0.1 mg morphine. In three trials, opioids enhanced MMO more than sodium hyaluronate. All studies exhibited low RoB. Certainty of evidence was moderate in six RCTs and low in three.</p><p><strong>Conclusion: </strong>There is no credible evidence for the benefit of intra-articular opioid-injections for managing TMJ nociception.</p><p><strong>Protocol registration: </strong>www.crd.tork.ac.uk/prospero identified is CRD42024598035.</p>","PeriodicalId":20000,"journal":{"name":"Pain management","volume":" ","pages":"441-447"},"PeriodicalIF":1.4,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12218567/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144267015","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}